UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 99

Sortiert nach

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist

Nature (London), 2017-06, Vol.546 (7659), p.528-532

2017

Link zum Volltext

Verfügbarkeit prüfen

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

Trends in molecular medicine, 2011-02, Vol.17 (2), p.88-96

2011

Link zum Volltext

Verfügbarkeit prüfen

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A

Science (American Association for the Advancement of Science), 2018-04, Vol.360 (6386), p.336-341

2018

Link zum Volltext

Verfügbarkeit prüfen

A FimH Inhibitor Prevents Acute Bladder Infection and Treats Chronic Cystitis Caused by Multidrug-Resistant Uropathogenic Escherichia coli ST131

The Journal of infectious diseases, 2013-09, Vol.208 (6), p.921-928

2013

Link zum Volltext

Verfügbarkeit prüfen

A host receptor enables type 1 pilus-mediated pathogenesis of Escherichia coli pyelonephritis

PLoS pathogens, 2021-01, Vol.17 (1), p.e1009314-e1009314

2021

Link zum Volltext

Verfügbarkeit prüfen

Lead Optimization Studies on FimH Antagonists: Discovery of Potent and Orally Bioavailable Ortho-Substituted Biphenyl Mannosides

Journal of medicinal chemistry, 2012-04, Vol.55 (8), p.3945-3959

2012

Link zum Volltext

Verfügbarkeit prüfen

Combinatorial Small-Molecule Therapy Prevents Uropathogenic Escherichia coli Catheter-Associated Urinary Tract Infections in Mice

Antimicrobial Agents and Chemotherapy, 2012-09, Vol.56 (9), p.4738-4745

2012

Link zum Volltext

Verfügbarkeit prüfen

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Molecular cancer therapeutics, 2008-09, Vol.7 (9), p.2955-2966

2008

Link zum Volltext

Verfügbarkeit prüfen

Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets

Bioorganic & medicinal chemistry, 2015-05, Vol.23 (10), p.2328-2343

2015

Link zum Volltext

Verfügbarkeit prüfen

Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins

Analytical chemistry (Washington), 2017-02, Vol.89 (4), p.2636-2644

2017

Link zum Volltext

Verfügbarkeit prüfen

Extracellular targeting of cell signaling in cancer: strategies directed at MET and RON receptor tyrosine kinases

First edition., 2018

Link zum Volltext

Verfügbarkeit prüfen

Distinguishing the Contribution of Type 1 Pili from That of Other QseB-Misregulated Factors when QseC Is Absent during Urinary Tract Infection

Infection and Immunity, 2012-08, Vol.80 (8), p.2826-2834

2012

Link zum Volltext

Verfügbarkeit prüfen

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials

Expert opinion on investigational drugs, 2008-09, Vol.17 (9), p.1331-1340

2008

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer

ACS medicinal chemistry letters, 2014-11, Vol.5 (11), p.1219-1224

2014

Link zum Volltext

Verfügbarkeit prüfen

Aspartyl Protease Inhibitors as Anti-Filarial Drugs

Pathogens (Basel), 2022-06, Vol.11 (6), p.707

2022

Link zum Volltext

Verfügbarkeit prüfen

An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease

Pathogens (Basel), 2021-01, Vol.10 (1), p.71

2021

Link zum Volltext

Verfügbarkeit prüfen

Hepatocyte growth factor activator inhibitor-2 stabilizes Epcam and maintains epithelial organization in the mouse intestine

Communications biology, 2019-01, Vol.2 (1), p.11, Article 11

2019

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-Based Macrocyclic Inhibitors of Serine Proteases

Journal of medicinal chemistry, 2024-03, Vol.67 (6), p.4833-4854

2024

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections

Journal of medicinal chemistry, 2024-03, Vol.67 (5), p.3668-3678

2024

Link zum Volltext

Verfügbarkeit prüfen

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease

Expert opinion on drug discovery, 2017-07, Vol.12 (7), p.711-731

2017

Link zum Volltext

Verfügbarkeit prüfen

Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis

Journal of medicinal chemistry, 2020-06, Vol.63 (11), p.6144-6163

2020

Link zum Volltext

Verfügbarkeit prüfen

Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection

Proceedings of the National Academy of Sciences - PNAS, 2018-03, Vol.115 (12), p.E2819-E2828

2018

Link zum Volltext

Verfügbarkeit prüfen

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells

Proceedings of the National Academy of Sciences - PNAS, 2021-10, Vol.118 (43)

2021

Link zum Volltext

Verfügbarkeit prüfen

Antivirulence C‑Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections

Journal of medicinal chemistry, 2016-10, Vol.59 (20), p.9390-9408

2016

Link zum Volltext

Verfügbarkeit prüfen

Biphenyl Gal and GalNAc FmlH Lectin Antagonists of Uropathogenic E. coli (UPEC): Optimization through Iterative Rational Drug Design

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.467-479

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 99

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Englisch
(99)
Japanisch
(14)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(76)
Life Sciences & Biomedicine
(63)
Pharmacology & Pharmacy
(33)
Animals
(31)
Chemistry, Medicinal
(28)
Humans
(27)
Mice
(22)
Cell Biology
(19)
Structure-Activity Relationship
(19)
Medicine, Research & Experimental
(17)
Oncology
(17)
Research & Experimental Medicine
(17)
Chemistry
(13)
Physical Sciences
(13)
Cancer
(12)
Drug Design
(11)
Drug Discovery
(11)
Female
(10)
Models, Molecular
(10)
Urinary Tract Infections - Drug Therapy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A

A FimH Inhibitor Prevents Acute Bladder Infection and Treats Chronic Cystitis Caused by Multidrug-Resistant Uropathogenic Escherichia coli ST131

A host receptor enables type 1 pilus-mediated pathogenesis of Escherichia coli pyelonephritis

Lead Optimization Studies on FimH Antagonists: Discovery of Potent and Orally Bioavailable Ortho-Substituted Biphenyl Mannosides

Combinatorial Small-Molecule Therapy Prevents Uropathogenic Escherichia coli Catheter-Associated Urinary Tract Infections in Mice

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets

Click Chemistry Reagent for Identification of Sites of Covalent Ligand Incorporation in Integral Membrane Proteins

Extracellular targeting of cell signaling in cancer: strategies directed at MET and RON receptor tyrosine kinases

Distinguishing the Contribution of Type 1 Pili from That of Other QseB-Misregulated Factors when QseC Is Absent during Urinary Tract Infection

Keeping checkpoint kinases in line: new selective inhibitors in clinical trials

Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer

Aspartyl Protease Inhibitors as Anti-Filarial Drugs

An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical Disease

Hepatocyte growth factor activator inhibitor-2 stabilizes Epcam and maintains epithelial organization in the mouse intestine

Mechanism-Based Macrocyclic Inhibitors of Serine Proteases

Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections

Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease

Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic Toxoplasmosis

Structure-based discovery of glycomimetic FmlH ligands as inhibitors of bacterial adhesion during urinary tract infection

A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells

Antivirulence C‑Mannosides as Antibiotic-Sparing, Oral Therapeutics for Urinary Tract Infections

Biphenyl Gal and GalNAc FmlH Lectin Antagonists of Uropathogenic E. coli (UPEC): Optimization through Iterative Rational Drug Design

Suchergebnisse filtern